serinoyl-aspartyl-lysinoyl-proline | 105464-22-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: serinoyl-aspartyl-lysinoyl-proline
• 英文别名: seryl-aspartyl-lysyl-proline；SerAspLysPro；Ser-Asp-Lys-Pro；(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid
• CAS: 105464-22-0
• 化学式: C₁₈H₃₁N₅O₈
• 分子量: 445.473
• InChiKey: CJNCVBHTDXKTMJ-CYDGBPFRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -9.6
• 重原子数：
  31
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.72
• 拓扑面积：
  225
• 氢给体数：
  7
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  BocS(OBzl)D(OBzl)K(Z)POBzl 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 、 二氯甲烷 、 水 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 23.0h， 生成 serinoyl-aspartyl-lysinoyl-proline
  参考文献：
  名称：

  Synthesis and activity of NAcSerAspLysPro analogs on cellular interactions between T-cell and erythrocytes in rosette formation

  摘要：

  Analogues of NAcSerAspLysPro (AcSDKP), a natural regulator of hematopoiesis isolated from fetal calf bone marrow, were synthesized. The biological activity of these molecules were evaluated in vitro in the rosette assay, which measures the interaction between human Jurkat T-cells and sheep red blood cells. In this test, the tripeptide SerAspLys was the most efficient. Inhibitory activity was detected at the concentration 10(-14) M for the analogue and at 10(-9) M for the parent tetrapeptide. The dipeptide NAcSerAsp still showed activity but at much higher doses (10(-6) M). Substitution of polar amino acids led mostly to inactive molecules. Thus, replacement of Ser by Ala, or Lys by Orn yielded completely inactive compounds and replacement of Asp by Glu decreased the activity (10(-6) M). The present study gives an insight into the role of individual amino acids of AcSDKP in the inhibition of the rosette formation which implicates interactions with T-cell CD2 glycoprotein.

  DOI：

  10.1021/jm00170a012

文献信息

• CRYSTAL STRUCTURE OF AN ANGIOTENSIN-CONVERTING ENZYME (ACE) AND USES THEREOF
  申请人：UNIVERSITY OF BATH

  公开号：EP1539815A1

  公开（公告）日：2005-06-15
• SELF-ASSEMBLING PEPTIDE SCAFFOLDS
  申请人：Tavakol Shima

  公开号：US20170290951A1

  公开（公告）日：2017-10-12

  A mixture for an injectable scaffold may include a self-assembling core and an additive. The additive may include an angiogenic agent, a small molecule drug, and/or an anti-inflammatory agent. The scaffold can be applied to sites where bone growth is desired.
• Dermatological Cosmetic Composition Comprising an SDKP Peptide or an Analog Thereof
  申请人：RPM Dermatologie

  公开号：US20210205199A1

  公开（公告）日：2021-07-08

  The invention relates to a lipid nanoparticle comprising an SDKP peptide conjugate or a biological peptide analog thereof, a method for obtaining said lipid nanoparticle, and the cosmetic use thereof as an anti-wrinkle agent or skin restructuring agent.
• [EN] CRYSTAL STRUCTURE OF AN ANGIOTENSIN-CONVERTING ENZYME (ACE) AND USES THEREOF<br/>[FR] STRUCTURE DE CRISTAL D'UNE ENZYME DE CONVERSION DE L'ANGIOTENSINE (ACE) ET SES UTILISATIONS
  申请人：UNIV BATH

  公开号：WO2004024765A1

  公开（公告）日：2004-03-25

  The present invention relates to a crystal of ACE protein. The present invention further relates to methods, processes, ACE modulators, pharmaceutical compositions and uses of the ACE crystal and the structure co-ordinates thereof.
• [EN] METHODS OF TREATMENT FOR PULMONARY FIBROSIS<br/>[FR] PROCÉDÉS DE TRAITEMENT D'UNE FIBROSE PULMONAIRE
  申请人：CEDARS SINAI MEDICAL CENTER

  公开号：WO2009149201A1

  公开（公告）日：2009-12-10

  The invention relates to compositions and methods for treating fibrosing lung diseases, reducing pulmonary cytokine production in animals, treating bleomycin induced lung disease and treating cancer. Specifically, the present subject matter incorporates inactivation of the N-terminal site of an angiotensin-converting enzyme and/or administration of AcSDKP.